¼¼°èÀÇ Àα¸ ½ºÅ©¸®´× ½ÃÀå : Á¦Ç° À¯Çüº°, ¼ºº°, ¿¬·Éº°, °¡°Ý À¯Çüº°, »ç¾÷º°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À² ¿¹Ãø(2024-2032³â)
Population Screening Market, By Product Type, By Gender, By Age, By Pricing Type, By Business, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1515388
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 398 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,589,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,565,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,977,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

Àα¸ ½ºÅ©¸®´× ½ÃÀå ±Ô¸ð´Â 2023³â 261¾ï 3,423¸¸ ´Þ·¯·Î 2024³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 5.4%·Î È®´ë

Àα¸ ½ºÅ©¸®´× ½ÃÀå - ½ÃÀå ¿ªÇÐ

¸¸¼º ¹× ºñ°¨¿°¼º ÁúȯÀÇ È®»êÀº ½ÃÀå ¼ö¿ä¸¦ ÃËÁø

¸¸¼º Áúȯ°ú ºñ Àü¿°¼º ÁúȯÀÇ ¸¸¿¬ÀÌ ÁøÇàµÇ°í ½ºÅ©¸®´× Á¦Ç° ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ´Â ÀÇ»ç¿Í ȯÀÚ ¸ðµÎ°¡ ÀÌ·¯ÇÑ Áúº´À» Á¶±â¿¡ ¹ß°ßÇÏ´Â ¹æ¹ýÀ» ã°í Àֱ⠶§¹®ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Áúº´ÀÇ Èı⿡´Â Á¾Á¾ ´õ ºñ½Ñ Ä¡·á°¡ ÇÊ¿äÇϱ⠶§¹®¿¡ Á¶±â ¹ß°ßÀº Ä¡·á ºñ¿ëÀ» Å©°Ô ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. COVID-19ÀÇ ´ëÀ¯ÇàÀº Áý´Ü °ËÁø ½ÃÀå¿¡µµ ÂѰܳµ½À´Ï´Ù. ¿¹¸¦ µé¾î Hayatt Med-Tech´Â 2021³â 6¿ù Hayatt Thermox-D¸¦ °³¹ßÇß½À´Ï´Ù. ÀÌ ¿ÏÀüÈ÷ ÀÚµ¿È­µÈ ÀåÄ¡´Â ¿©·¯ COVID-19 ¸Å°³º¯¼ö¸¦ ½ºÅ©¸®´×Çϰí 12ÃÊ À̳»¿¡ °¨¿° °¡´É¼ºÀ» È®ÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ »ç¿ë ÈÄ ¸Å¹ø ¼Òµ¶µË´Ï´Ù. ¶ÇÇÑ »õ·Î¿î ºÐ¼®±â¼úÀÇ °³Ã´ÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÈ­ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾Ï¿¡ Æ¯È­ÇØ º¸¸é, ±× À¯º´·üÀÇ »ó½ÂÀÌ ÀÌ ½ÃÀåÀÇ ÁÖµÈ ÃËÁø¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)ÀÇ º¸°í¿¡ µû¸£¸é ¾ÏÀº ¼¼°è 2À§ÀÇ »çÀÎÀÔ´Ï´Ù. 2020³â¸¸À¸·Îµµ »õ·Ó°Ô ¾ÏÀ¸·Î Áø´ÜµÈ ȯÀÚ¼ö´Â 1,930¸¸¸íÀ¸·Î, »ç¸ÁÀÚ¼ö´Â 996¸¸¸íÀÔ´Ï´Ù. ±¹Á¦¾Ï¿¬±¸±â°ü(IARC)Àº ÀÌ ¼öÄ¡°¡ ´õ¿í »ó½ÂÇØ 2025³â±îÁö 2,190¸¸¸í, 2030³â±îÁö 2,460¸¸¸íÀÌ »õ·Ó°Ô ¾ÏÀ¸·Î Áø´ÜµÉ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ¾Ï Áø´ÜÀÇ ´ëÆøÀûÀÎ Áõ°¡´Â °¢±¹ Á¤ºÎ¸¦ »õ·Î¿î ¾Ï °ËÁø ÇÁ·Î±×·¥ÀÇ ½ÃÀÛÀ¸·Î ÇâÇÏ°Ô ÇÏ¿© Áý´Ü °ËÁø ½ÃÀåÀ» ´õ¿í È®´ë½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Áý´Ü °ËÁø ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

¿ì¸®ÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®°¡ °øÀ¯ÇÑ ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032³â)¿¡ ¾à 5.4%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

Á¦Ç° À¯Çüº°·Î Çϵå¿þ¾î Àåºñ(Àåºñ, ŰƮ, Ĩ) lÀº 2023³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» º¸¿©ÁÙ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼ºº°¿¡¼­ 2023³â¿¡´Â ¿©¼ºÀÌ ÁÖ¿ä À¯ÇüÀ̾ú½À´Ï´Ù.

¿¬·Éº°·Î´Â 65¼¼ ÀÌ»óÀÌ 2023³âÀÇ ÁÖ¿ä À¯ÇüÀ̾ú½À´Ï´Ù.

ºñÁî´Ï½º ¼¼ºÐÈ­¸¦ ±â¹ÝÀ¸·Î 2023³â¿¡´Â º´¿øÀÌ ÁÖ¿ä À¯ÇüÀ̾ú½À´Ï´Ù.

°¡°Ý À¯Çüº°·Î´Â 2023³â¿¡´Â '´ëÁß'ÀÌ ÁÖ¿ä À¯ÇüÀ̾ú½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â ¸ÅÃâ¿¡¼­ ÃÖ°í

Àα¸ ½ºÅ©¸®´× ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

¼¼°è Àα¸ ½ºÅ©¸®´× ½ÃÀåÀº Á¦Ç° À¯Çü, ¼ºº°, ¿¬·É, °¡°Ý À¯Çü, ºñÁî´Ï½º ¹× Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº Á¦Ç° À¯Çü¿¡ µû¶ó ¼¼ °¡Áö·Î ºÐ·ùµË´Ï´Ù. Çϵå¿þ¾î Àåºñ À¯Çü(Àåºñ, ŰƮ, Ĩ) ºÎ¹®Àº 2023³â ÃÖ´ë ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ ¼ºÀåÀº ´õ ¸¹Àº Áúº´ÀÇ Áý´Ü ½ºÅ©¸®´×À»À§ÇÑ Àåºñ¿Í »õ·Î¿î °Ë»ç ŰƮÀÇ ½ÂÀÎÀ¸·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 7¿ù, Fujifilm Corporation´Â Àεµ¿¡¼­ 2°³ÀÇ »õ·Î¿î ¾Ï °ËÁø ½Ã¼³À» Ãâ¹ü½ÃÄ×°í, ½ÇÇè½Ç ¼³Ä¡¸¦ À§ÇÑ Çϵå¿þ¾î¿Í Àåºñ ¼ö¿ä¸¦ Áõ°¡½ÃÄÑ ½ÃÀåÀ» °ßÀÎÇß½À´Ï´Ù. °Ô´Ù°¡ 2021³â 3¿ù¿¡´Â Indigital Technologies°¡ ¸®½ºÅ© °èÃþÈ­¸¦ À§ÇÑ ÇÚµåÇïµå ½ºÅ©¸®´× ÀåºñÀÎ Kribado¸¦ Ãâ½ÃÇÏ¿© ÀÇ·á±â°ü°ú °³¾÷ÀǸ¦ À§ÇÑ NGS Çൿ ¼³Á¤ Àåºñ¸¦ Ãâ½ÃÇß½À´Ï´Ù. Ŭ¸®´Ð°ú º´¿ø¿¡¼­ ÀÌ·¯ÇÑ ±â°èÀÇ °¡¿ë¼ºÀÌ ³ô¾ÆÁü¿¡ µû¶ó Á¶±â ¸®½ºÅ© ½Äº°À» À§ÇÑ °ü·Ã Á¶Ä¡ÀÇ Ã¤¿ëÀÌ ÃËÁøµÇ¾î, ÇコÄÉ¾î ½Ã½ºÅÛÀÇ ÀüüÀûÀÎ ÀçÁ¤ ºÎ´ãÀÇ °æ°¨¿¡ °øÇåÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

½ÃÀåÀº »ç¾÷ ³»¿ë¿¡ µû¶ó ¼¼ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. º´¿ø, Á¶»ç ±â°ü, Áø´Ü ½ÇÇè½Ç. 2023³â¿¡´Â º´¿ø ºÎ¹®ÀÌ °¡Àå Å« ÆÇ¸Å Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. º´¿ø¿¡´Â ȯÀÚ°¡ ÀûÀýÇÑ Áý´Ü ½ºÅ©¸®´× °Ë»ç¸¦ ¼±ÅÃÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÏ´Â Àü¹®°¡°¡ ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, ´ÙÁß °Ë»ç ¿É¼ÇÀÇ °¡¿ë¼º, º¸´Ù È¿°úÀûÀΠȯÀÚ ½ºÅ©¸®´×À» À§ÇÑ »õ·Î¿î °Ë»çÀÇ Ãâ½ÃÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 7¿ù, Ÿ¹Ð ³ªµÎ ÁÖ Á¤ºÎ ¸ÖƼ ½´ÆÛ ½ºÆä¼ÈƼ º´¿ø(TNGMSSH)Àº ±×·¹ÀÌÅÍ Ã¾³ªÀÌ °ø»çÀÇ 1Â÷ °Ç°­ ¼¾ÅÍ¿¡ ºñÁ¤»óÀûÀÎ ½ºÅ©¸®´×À» À§ÇØ ´õ ¸¹Àº ¿©¼ºÀ» ¼Ò°³Çϵµ·Ï ±ÇÀåÇß½À´Ï´Ù. ÀÌ º´¿øÀº °í±Þ ÆÐŰÁöÀÇ °Ç°­ Áø´Ü¼¾Å͸¦ ÅëÇØ Á¾ÇÕ Ç÷¾× °Ë»ç, À¯ÀüÀÚ ¹ÙÀÌ¿À ¸¶Ä¿ °Ë»ç, ÃÊÀ½ÆÄ °Ë»ç µîÀÇ °Ë»ç¸¦ 12.30 USD·Î Á¦°øÇÕ´Ï´Ù.

Àα¸ ½ºÅ©¸®´× ½ÃÀå - Áö¸®Àû ÅëÂû

ÀÌ ½ÃÀåÀÇ Áö¸®Àû ºÐÆ÷´Â ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¸¦ ´Ù·ì´Ï´Ù. ÀÌ Áö¿ªÀÇ ±¹°¡µéÀº Ãß°¡ ½ÃÀå ºÎ¹®À» ´ë·«ÀûÀ¸·Î Á¤ÀÇÇÕ´Ï´Ù. ºÏ¹Ì´Â 2023³â¿¡ Å« ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇÏ°í ½ÃÀåÀ» µ¶Á¡ÇÏ´Â ÀÚ¼¼ÀÔ´Ï´Ù. ÀÌ ¼ºÀåÀº ÁÖ·Î Áúº´ÀÇ ÁøÇàÀ» ¸·±â À§ÇØ Á¤ºÎ°¡ ½Ç½ÃÇÑ ¿¹¹æ ´ëÃ¥ ¶§¹®ÀÔ´Ï´Ù. ºÏ¹Ì¿¡¼­´Â ¹Ì±¹°ú ij³ª´Ù°¡ Áý´Ü °ËÁøÀÇ ÁÖ¿ä ½ÃÀåÀÌÁö¸¸, À̴ ȯÀÚ¿Í ÀÇ»ç »çÀÌ¿¡¼­ °ËÁøÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô±â ¶§¹®ÀÔ´Ï´Ù. °áÇÙ(TB) ¿¹¹æÀº ¹Ì±¹ °ËÁø·üÀ» ³ôÀÌ´Â Áß¿äÇÑ ¿äÀÎÀÔ´Ï´Ù. ¶ÇÇÑ 2019³â¿¡´Â CDC¿Í(NTCA) Àü±¹ °áÇÙ °ü¸®ÀÚ Çùȸ°¡ ÀÇ·á Á¾»çÀÚÀÇ °áÇÙ ½ºÅ©¸®´×, °Ë»ç ¹× Ä¡·á¿¡ °üÇÑ ±ÇÀå »çÇ×À» ¾÷µ¥ÀÌÆ®Çß½À´Ï´Ù. ±× °á°ú, Áúº´ÀÇ Á¶±â Áø´Ü°ú Ä¡·á ½ºÅ©¸®´×À» Áõ°¡½Ã۱â À§ÇÑ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê°¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Àα¸ ½ºÅ©¸®´× ½ÃÀå - °æÀï ±¸µµ:

Æ÷ǽ·¹ÀÌ¼Ç ½ºÅ©¸®´× ½ÃÀå¿¡¼­ ´ë±â¾÷Àº Àü·«Àû ÆÄÆ®³Ê½Ê, ºó¹øÇÑ Á¦Ç° ¹ßÇ¥ ¹× ±â¼ú Áøº¸¸¦ ÅëÇØ ¿ìÀ§¸¦ À¯ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á ±â°ü ¹× ¿¬±¸ ±â°ü°úÀÇ Á¦ÈÞ´Â ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ ¼¼Æ®¿¡ ´ëÇÑ ¾×¼¼½º¸¦ Á¦°øÇϰí Á¾ÇÕÀûÀÎ ½ºÅ©¸®´× ÇÁ·Î±×·¥ÀÇ °³¹ßÀ» ÃËÁøÇÕ´Ï´Ù. Á¦Ç° ¹ßÇ¥¸¦ ÅëÇÑ Áö¼ÓÀûÀÎ Çõ½ÅÀº »õ·Î¿î ÇコÄÉ¾î ¿ä±¸»çÇ׿¡ ºÎÇÕÇÏ´Â Á¦Ç° Á¦°øÀ» º¸ÀåÇϸç, Á¶»ç ¹æ¹ý¿¡ ´ëÇÑ ÅõÀÚ´Â »õ·Î¿î ½ºÅ©¸®´× ±â¼ú°ú ±â¼ú ޱ¸¸¦ ÃËÁøÇÕ´Ï´Ù. Àü·«Àû Àμö´Â ±â¾÷ÀÇ ´É·ÂÀ» °­È­ÇÏ°í ½ÃÀå¿¡¼­ÀÇ ÁöÀ§¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº ½Å±Ô ¹× ±âÁ¸ ÆÄÆ®³Ê½ÊÀ» ÃËÁøÇϰí, »õ·Î¿î Áö¿ª¿¡ ÁøÀÔÇϰí, ÇâÈÄ °æÁ¦ÀûÀ¸·Î À¯¸ÁÇÑ Áö¿ª¿¡¼­ÀÇ Àü·«Àû Á¦ÈÞ¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Àα¸ ½ºÅ©¸®´× ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Àα¸ ½ºÅ©¸®´×ÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå Àα¸ ½ºÅ©¸®´× »ê¾÷ÀÇ Á¶»ç

Á¦5Àå Àα¸ ½ºÅ©¸®´× ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå Àα¸ ½ºÅ©¸®´× ½ÃÀå »óȲ

Á¦7Àå Àα¸ ½ºÅ©¸®´× ½ÃÀå-Á¦Ç° À¯Çüº°

Á¦8Àå Àα¸ ½ºÅ©¸®´× ½ÃÀå- ¼ºº°

Á¦9Àå Àα¸ ½ºÅ©¸®´× ½ÃÀå - ¿¬·Éº°

Á¦10Àå Àα¸ ½ºÅ©¸®´× ½ÃÀå - °¡°Ý À¯Çüº°

Á¦11Àå Àα¸ ½ºÅ©¸®´× ½ÃÀå- »ç¾÷º°

Á¦12Àå Àα¸ ½ºÅ©¸®´× ½ÃÀå-Áö¿ªº°

Á¦13Àå ÁÖ¿ä º¥´õ ºÐ¼® - Àα¸ ½ºÅ©¸®´× ¾÷°è

Á¦14Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Population Screening Market size was valued at USD 26,134.23 Million in 2023, expanding at a CAGR of 5.4% from 2024 to 2032.

Population screening is a public health strategy aimed at detecting disease or risk factors in a specific group of people who do not yet have symptoms. It involves systematically testing a large, defined population to identify individuals at higher risk of developing a particular condition. The goal is to enable early intervention, thereby improving health outcomes and reducing the burden of disease. Common examples include screenings for cancer, cardiovascular diseases, and genetic disorders. By identifying and managing diseases at an early stage, population screening can help lower treatment costs, enhance quality of life, and increase survival rates.

Population Screening Market- Market Dynamics

The increasing prevalence of chronic and non-communicable diseases propels market demand

Chronic and non-communicable diseases are becoming more widespread, which is creating a larger market for screening products. This is because both doctors and patients are looking for ways to identify these diseases early. Early detection can significantly reduce treatment costs, as later stages of these diseases often require more expensive interventions. The COVID-19 pandemic has even provided a boost to the population screening market. For example, Hayatt Med-Tech created the Hayatt Thermox-D in June 2021. This fully automated device can screen for multiple COVID-19 parameters and identify potential infections within 12 seconds. Additionally, it disinfects itself after each use. Furthermore, the development of new analytical technologies is expected to accelerate market growth. Looking specifically at cancer, its rising prevalence is a major driver for this market. The World Health Organization (WHO) reports that cancer is the world's second leading cause of death. In 2020 alone, there were 19.3 million fresh cancer cases diagnosed, with 9.96 million deaths. The International Agency for Research on Cancer (IARC) predicts these numbers to climb even higher, estimating 21.9 million new cases by 2025 and a staggering 24.6 million by 2030. This significant increase in cancer diagnoses is expected to push governments towards launching new cancer screening programs, further expanding the population screening market.

Population Screening Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.4% over the forecast period (2024-2032)

Based on Product Type segmentation, hardware equipment (instruments, kits, chips)l was predicted to show maximum market share in the year 2023

Based on Gender segmentation,= Female was the leading type in 2023

Based on Age segmentation, 65+ was the leading type in 2023

Based on Business segmentation, the hospital was the leading type in 2023

Based on Pricing Type segmentation, Mass was the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Population Screening Market- Segmentation Analysis:

The Global Population Screening Market is segmented based on Product Type, Gender, Age, Pricing Type, Business and Region.

The market is divided into three categories based on Product Type: Hardware Equipment (Instrument, Kits, Chips), Testing / Lab (Services) and Analytics / Interpretation (Personalization And Interpretation). The hardware equipment type (instruments, kits, chips) segment held the largest revenue share in 2023. This growth can be attributed to the approval of equipment and novel test kits for the population screening of more diseases. For instance, in July 2022, Fujifilm Corporation inaugurated two new cancer screening facilities in India, which increased the demand for hardware and equipment for laboratory setups, driving the market. Additionally, in March 2021, Indigital Technologies launched Kribado, a handheld screening device, for risk stratification and NGS behavior settings devices for healthcare companies and practitioners. The increasing availability of such machines in clinics and hospitals is expected to boost the adoption of related procedures for early risk identification, helping ease the overall financial burden on healthcare systems.

The market is divided into three categories based on Business: Hospitals, Research Institutes, and Diagnostic Labs. The hospital segment accounted for the largest revenue share in 2023. Hospitals have experts who assist patients in selecting appropriate population screening tests. Market growth is driven by the increasing prevalence of chronic diseases, the availability of multiple testing options, and the launch of novel tests for more effective patient screening. For example, in July 2022, the Tamil Nadu Government Multi-Super Specialty Hospital (TNGMSSH) encouraged primary health centers in Greater Chennai Corporation to refer more women for anomaly screening. The hospital offers tests such as comprehensive blood tests, genetic biomarker testing, and ultrasound scans at USD 12.30 through its advanced master health checkup center package.

Population Screening Market- Geographical Insights

The geographic distribution of this market covers North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Countries within these regions broadly define further market segments. North America is poised to dominate the market, accounting for a significant revenue share in 2023. This growth is mainly attributed to preventive measures undertaken by governments to stop disease progression. In North America, the U.S. and Canada are major markets for population screening due to high awareness about the benefits of screening among patients and physicians. Tuberculosis (TB) prevention is a significant factor boosting the screening rate in the United States. Also, in 2019, the CDC and (NTCA) National Tuberculosis Controllers Association updated their recommendations for TB screening, testing, and treatment of healthcare personnel. Consequently, government initiatives to increase early disease diagnosis and treatment screenings are expected to drive market growth.

Population Screening Market- Competitive Landscape:

In the Population Screening Market, major players maintain dominance through strategic partnerships, frequent product launches, and technological advancements. Collaborations with healthcare institutions and research organizations enable access to extensive datasets, facilitating the development of comprehensive screening programs. Continuous innovation through product launches ensures offerings align with emerging healthcare needs, while R&D investments drive the exploration of new screening methodologies and technologies. Strategic acquisitions bolster companies' capabilities, enhancing their market position. Key players in the market are focusing on fostering new and existing partnerships, entering new territories, and strategic collaborations in upcoming and economically viable regions.

Recent Developments:

In April 2022, Quest Diagnostics partnered with (IRIS) Intelligent Retinal Imaging Systems to provide diabetic retinopathy testing services through its patient service centers in the United States. This partnership is expected to have a positive impact on the market.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL POPULATION SCREENING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Agilent Technologies, Inc.

Thermo Fisher Scientific, Inc.

QIAGEN

F. Hoffmann-La Roche Ltd.

Quest Diagnostics

Illumina, Inc.

ARUP Laboratories

Novogene Co., Ltd.

LGC Limited

Gene by Gene, Ltd.

Others

GLOBAL POPULATION SCREENING MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL POPULATION SCREENING MARKET, BY GENDER- MARKET ANALYSIS, 2019 - 2032

GLOBAL POPULATION SCREENING MARKET, BY AGE- MARKET ANALYSIS, 2019 - 2032

GLOBAL POPULATION SCREENING MARKET, BY PRICING TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL POPULATION SCREENING MARKET, BY BUSINESS- MARKET ANALYSIS, 2019 - 2032

GLOBAL POPULATION SCREENING MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. Population Screening Market Overview

2. Executive Summary

3. Population Screening Key Market Trends

4. Population Screening Industry Study

5. Population Screening Market: COVID-19 Impact Analysis

6. Population Screening Market Landscape

7. Population Screening Market - By Product Type

8. Population Screening Market - By Gender

9. Population Screening Market - By Age

10. Population Screening Market - By Pricing Type

11. Population Screening Market - By Business

12. Population Screening Market- By Geography

13. Key Vendor Analysis- Population Screening Industry

14. 360 Degree Analyst View

15. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â